Home » Stocks » Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc. (XENE)

Stock Price: $10.54 USD -0.37 (-3.39%)
Updated Aug 14, 2020 12:11 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 368.85M
Revenue (ttm) 27.29M
Net Income (ttm) -27.91M
Shares Out 34.99M
EPS (ttm) -0.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $10.54
Previous Close $10.91
Change ($) -0.37
Change (%) -3.39%
Day's Open 10.88
Day's Range 10.11 - 10.89
Day's Volume 83,588
52-Week Range 7.00 - 18.45

More Stats

Market Cap 368.85M
Enterprise Value 167.01M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 34.99M
Float 22.35M
EPS (basic) -0.96
EPS (diluted) -0.90
FCF / Share -0.37
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 917,562
Short Ratio 11.12
Short % of Float 3.31%
Beta 1.23
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 13.52
PB Ratio 2.13
Revenue 27.29M
Operating Income -29.23M
Net Income -27.91M
Free Cash Flow -12.84M
Net Cash 201.84M
Net Cash / Share 5.77
Gross Margin -117.31%
Operating Margin -107.10%
Profit Margin -98.60%
FCF Margin -47.06%
ROA -11.54%
ROE -20.51%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$23.57*
(123.62% upside)
Low
22.0
Current: $10.54
High
25.0
Target: 23.57
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue6.83-0.311.8015.5828.3727.3614.316.92
Revenue Growth---82.75%-88.43%-45.09%3.71%91.19%106.82%-
Gross Profit6.83-0.311.8015.5828.3727.3614.316.92
Operating Income-42.82-38.04-32.58-24.82-9.3611.119.71-3.15-12.11
Net Income-41.60-34.50-30.70-23.00-15.7513.0212.03-4.30-11.99
Shares Outstanding25.9419.4317.9915.4914.283.171.341.331.32
Earnings Per Share-1.54-1.63-1.72-1.48-1.103.281.91-3.24-9.06
EPS Growth-----71.73%---
Operating Cash Flow-4.63-34.72-28.73-19.57-18.100.27-3.3245.57-13.69
Capital Expenditures-1.24-0.51-0.32-0.28-0.55-1.53-0.15-0.52-0.29
Free Cash Flow-5.87-35.23-29.04-19.85-18.65-1.26-3.4745.05-13.98
Cash & Equivalents14111943.6764.1558.6584.0449.2860.160.00
Total Debt16.4515.016.80----1.67-
Net Cash / Debt12510436.8664.1558.6584.0449.2858.500.00
Assets14812246.1267.4963.9587.4254.4963.31-
Liabilities55.7219.1310.193.592.9214.6413350.68-
Book Value91.9810335.9363.9061.0372.78-78.37-89.87-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Xenon Pharmaceuticals Inc.
Country Canada
Employees 100
CEO Simon Neil Pimstone

Stock Information

Ticker Symbol XENE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: XENE
IPO Date November 5, 2014

Description

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is Phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy. The company's product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in Phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase I clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop first-in-class treatments for epilepsy. The company was founded in 1996 and is headquartered in Burnaby, Canada.